Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Guardian - UK

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.92%. US stock indexes Tuesday finished sharply lower. Signs of persistent wage pressure pushed bond...

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Zepbound Shows Promise In Treating Sleep Apnea

Eli Lilly's Zepbound drug shows promise in treating obstructive sleep apnea by reducing symptoms and promoting weight loss.

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say

The Guardian - AU

inkl

Read news from The Economist, FT, and more,
with one subscription

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Stocks Slide After U.S. Unemployment Report

Stocks Slide After U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. Stock indexes are lower this afternoon, after the S&P 500 and Nasdaq 100 posted new...

After a Morning Rally, Stocks Slide This Afternoon After Digesting the U.S. Unemployment Report

After a Morning Rally, Stocks Slide This Afternoon After Digesting the U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. Stock indexes are lower this afternoon, after the S&P 500 and Nasdaq 100 posted new...

S&P 500 and Nasdaq 100 Post Record Highs on Fed-Friendly U.S. Unemployment Report

S&P 500 and Nasdaq 100 Post Record Highs on Fed-Friendly U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.27%. Stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts

Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.29%. Stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Highly Awaited Alzheimer's Drug Hit By Delays

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

Stocks Climb on Lower U.S. and European Bond Yields

Stocks Climb on Lower U.S. and European Bond Yields

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.61%. Stock indexes this morning are seeing support from a decline in the 10-year...

Get all your
news in one place.

100’s of premium titles.
One news app.

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

International Business Times

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

The Guardian - US

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

As Tesla stock continues to underperform - now down more than 22% year-to-date - here are 3 mega-cap companies worthy of replacing the beleaguered EV giant in the elite group of mega-cap stocks known as the Magnificent Seven.

Get all your
news in one place.

100’s of premium titles.
One news app.

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

The Guardian - UK

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism

While the main indexes made modest moves Tuesday, Palantir Technologies soared 30% after earnings.

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

the Wall Street Journal

Warner Bros Discovery

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

315,698 stories

125,297 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play